zimberelimab
mAbexperimental
Clinical trial activity
63 trials · 41 clinical orgs · 0 marketing orgs
Phase 1
27
Phase 2
41
Phase 3
3
Phase 4
0
Earliest trial started Jul 24, 2018 (NCT03629756)
Timeline
Indications
Studied for
- Adenocarcinoma · Phase 3
- Bile Duct Neoplasms · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoid Tumor · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Merkel Cell · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Dyslipidemias · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 2
- Gestational Trophoblastic Disease · Phase 2
- Glioblastoma · Early Phase 1
- Head and Neck Neoplasms · Phase 1
- Healthy Volunteers · Phase 1
- Laryngeal Neoplasms · Phase 1
- Liposarcoma · Phase 2
- Liver Neoplasms · Phase 2
- Lung Diseases · Phase 2
- Lung Neoplasms · Phase 3
- Lymphoma · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Melanoma · Phase 2
- Mouth Neoplasms · Phase 1
- Multiple Myeloma · Phase 1
- Mutation · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 2
- Oropharyngeal Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 2
- Peritoneal Neoplasms · Phase 2
- Pharyngeal Neoplasms · Phase 1
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Rectal Neoplasms · Phase 2
- Sarcoma · Phase 2
- Sarcoma, Alveolar Soft Part · Phase 1
- Small Cell Lung Carcinoma · Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Thymoma · Phase 2
- Thyroid Carcinoma, Anaplastic · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- Adenosine A2b receptorANTAGONIST
Adenosine A2b receptor antagonist
- Adenosine A2a receptorANTAGONIST
Adenosine A2a receptor antagonist
- Programmed cell death protein 1ANTAGONIST
PD1
- Programmed cell death protein 1INHIBITOR
Programmed cell death protein 1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(C#N)cccc1-c1cc(-c2cn(Cc3cccc(C(C)(C)O)n3)nn2)nc(N)n1- Mol. weight
- 426.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4740383 ↗
- ChEMBLCHEMBL4297856 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07283848 | Phase 2 | Feb 1, 2026 | Arcus Biosciences, Inc., Gateway for Cancer Research, Harvard University |
| NCT07134556 | Phase 2 | Dec 8, 2025 | MedSIR, University of Bristol |
| NCT07152873 | Phase 1 | Oct 20, 2025 | Addpharma Inc. |
| NCT06790706 | Phase 2 | Oct 1, 2025 | University of Lyon |
| NCT06759649 | Phase 1 | Jan 7, 2025 | Compugen, Gilead Sciences |
| NCT06727565 | Phase 2 | Dec 31, 2024 | Arcus Biosciences, Inc., Gilead Sciences |
| NCT06528483 | Phase 2 | Dec 2, 2024 | Gilead Sciences, University of Milan |
| NCT06238921 | Phase 1/Phase 2 (Phase 2) | Oct 29, 2024 | Gilead Sciences, University of South Florida |
| NCT06431633 | Phase 2 | Oct 1, 2024 | Fundación GECP |
| NCT06532565 | Phase 1 | Jul 26, 2024 | Gilead Sciences |
| NCT06250036 | Phase 2 | Apr 1, 2024 | Gilead Sciences, Royal Marsden Hospital NHS Trust |
| NCT06133517 | Phase 2 | Mar 31, 2024 | Apices Soluciones S.L., University of Cantabria |
| NCT06155396 | Phase 2 | Mar 31, 2024 | RemeGen |
| NCT06166589 | Phase 2 | Jan 1, 2024 | Fudan University |
| NCT06048133 | Phase 2 | Dec 31, 2023 | Arcus Biosciences, Inc., Big Ten Cancer Research Consortium, Gilead Sciences, University of Wisconsin |
| NCT06107114 | Phase 2 | Dec 1, 2023 | Sun Yat-Sen University |
| NCT06120075 | Phase 1 | Dec 1, 2023 | Arcus Biosciences, Inc. |
| NCT06128460 | Phase 2 | Dec 1, 2023 | Fudan University |
| NCT06048484 | Phase 2 | Oct 31, 2023 | Arcus Biosciences, Inc., Columbia University |
| NCT05891171 | Phase 1 | Oct 13, 2023 | Arcus Biosciences, Inc. |
Showing 20 of 63 trials
Page 1 / 4
Organizations
Research & Development (41)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arcus Biosciences, Inc. | For profit | 35 | 20 | 3 | 2018 |
| Gilead Sciences | For profit | 16 | 6 | 3 | 2022 |
| Fudan University | Academic/Hospital | 4 | 4 | 1 | 2022 |
| Sun Yat-Sen University | Academic/Hospital | 3 | 3 | 1 | 2022 |
| Columbia University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Harvard University | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Addpharma Inc. | For profit | 1 | 1 | 1 | 2025 |
| Apices Soluciones S.L. | For profit | 1 | 0 | 1 | 2024 |
| Big Ten Cancer Research Consortium | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Compugen | For profit | 1 | 1 | 1 | 2025 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Duke University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Fundación GECP | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Gateway for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Infinity Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2018 |
| Lustgarten Foundation | Academic/Hospital | 1 | 0 | 1 | 2022 |
| MedSIR | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Otsuka | For profit | 1 | 1 | 1 | 2021 |
41 organizations
Page 1 / 3